Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of “Buy” by Analysts

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been given a consensus recommendation of “Buy” by the eight analysts that are covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $7.67.

Several analysts have issued reports on TRVI shares. Raymond James started coverage on Trevi Therapeutics in a report on Friday, August 30th. They set an “outperform” rating and a $9.00 price objective on the stock. Leerink Partners assumed coverage on shares of Trevi Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $7.00 price target on the stock. EF Hutton Acquisition Co. I raised shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, August 19th. Rodman & Renshaw began coverage on shares of Trevi Therapeutics in a research note on Thursday, June 13th. They set a “buy” rating and a $7.00 target price on the stock. Finally, Leerink Partnrs raised Trevi Therapeutics to a “strong-buy” rating in a research report on Monday, September 9th.

Trevi Therapeutics Price Performance

NASDAQ TRVI opened at $3.30 on Tuesday. Trevi Therapeutics has a 12 month low of $0.97 and a 12 month high of $4.00. The firm has a market capitalization of $232.44 million, a PE ratio of -9.71 and a beta of 0.96. The company’s 50 day simple moving average is $3.00 and its 200 day simple moving average is $2.91.

Trevi Therapeutics (NASDAQ:TRVI) last released its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). During the same period in the previous year, the business earned ($0.07) earnings per share. Sell-side analysts anticipate that Trevi Therapeutics will post -0.47 earnings per share for the current fiscal year.

Insider Transactions at Trevi Therapeutics

In other Trevi Therapeutics news, insider Thomas Sciascia sold 18,660 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the transaction, the insider now owns 220,315 shares in the company, valued at $608,069.40. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Trevi Therapeutics news, insider Thomas Sciascia sold 18,660 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $2.76, for a total transaction of $51,501.60. Following the completion of the sale, the insider now directly owns 220,315 shares in the company, valued at $608,069.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jennifer L. Good sold 10,981 shares of Trevi Therapeutics stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $3.02, for a total value of $33,162.62. Following the completion of the transaction, the chief executive officer now owns 213,313 shares in the company, valued at $644,205.26. The disclosure for this sale can be found here. In the last quarter, insiders sold 40,355 shares of company stock worth $116,663. 24.37% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Trevi Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Frazier Life Sciences Management L.P. increased its holdings in shares of Trevi Therapeutics by 7.3% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock worth $9,891,000 after purchasing an additional 500,000 shares during the period. Opaleye Management Inc. boosted its stake in shares of Trevi Therapeutics by 48.6% in the 4th quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock valued at $3,397,000 after purchasing an additional 829,100 shares in the last quarter. Oppenheimer & Co. Inc. acquired a new position in Trevi Therapeutics in the first quarter valued at about $208,000. Vanguard Group Inc. increased its holdings in shares of Trevi Therapeutics by 2.7% during the first quarter. Vanguard Group Inc. now owns 2,303,648 shares of the company’s stock worth $7,948,000 after buying an additional 60,249 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Trevi Therapeutics during the 1st quarter valued at $47,000. Institutional investors and hedge funds own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.